Maze Therapeutics, Inc.
MAZE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Market Cap | $699 | $698 | $698 |
| - Cash | $197 | $29 | $100 |
| + Debt | $27 | $50 | $32 |
| Enterprise Value | $528 | $719 | $630 |
| Revenue | $168 | $0 | $0 |
| % Growth | – | – | – |
| Gross Profit | $168 | $0 | $0 |
| % Margin | 100% | – | – |
| EBITDA | $61 | -$94 | -$107 |
| % Margin | 36.3% | – | – |
| Net Income | $52 | -$100 | -$115 |
| % Margin | 31.2% | – | – |
| EPS Diluted | 0.078 | -2.294 | -2.626 |
| % Growth | 103.4% | 12.6% | – |
| Operating Cash Flow | $76 | -$87 | -$99 |
| Capital Expenditures | -$1 | -$0 | -$2 |
| Free Cash Flow | $75 | -$87 | -$101 |